Introduction
Exemestane is a steroidal third generation aromatase inhibitor [1] utilized to block estrogen biosynthesis for the prevention and treatment of breast cancer . Effects involved in the antitumor effect of exemestane include stimulation of suicidal cell death or apoptosis [34] [35] [36] [37] [38] . Side effects of exemestane treatment include anemia [39] .
In theory, the anemia following exemestane treatment could result from stimulation of suicidal death of erythrocytes or eryptosis, which is characterized by cell membrane scrambling with phosphatidylserine translocation to the cell surface [40] . The cell membrane scrambling is typically paralleled by cell shrinkage [41] . Triggers of eryptosis include hyperosmotic shock [40] , oxidative stress [40] , energy depletion [40] , or exposure to a wide variety of xenobiotics [40, . The stimulation of eryptosis may involve increase of cytosolic Ca 2+ activity ([Ca 2+ ] i ) [40] , ceramide [40] , caspases [40, 106, 107] , casein kinase 1α [40] , Janus-activated kinase JAK3 [40] , protein kinase C [40] , and p38 kinase [40] . Eryptosis is inhibited by AMP activated kinase AMPK, cGMP-dependent protein kinase, PAK2 kinase [40] , and sorafenib/sunitinib sensitive kinases [40] . Enhanced eryptosis is observed in a variety of clinical conditions including fever [40] , iron deficiency [40] , dehydration [40] , hyperphosphatemia [40] , chronic kidney disease (CKD) [40] , hemolytic-uremic syndrome [40] , diabetes [40] , hepatic failure [42] , malignancy [40] , sepsis [40] , sickle-cell disease [40] , beta-thalassemia [40] , Hb-C and G6PD-deficiency [40] , as well as Wilson´s disease [40] .
The present study explored, whether exemestane influences eryptosis. To this end, human erythrocytes from healthy volunteers were exposed to exemestane and phosphatidylserine surface abundance, cell volume, [Ca 2+ ] i , ROS formation, and ceramide abundance determined by flow cytometry.
Materials and Methods

Erythrocytes, solutions and chemicals
Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The blood was centrifuged at 120 g for 20 min at 21 °C and the platelets and leukocytes-containing supernatant was disposed. Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO 4 , 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES; pH 7.4), 5 glucose, 1 CaCl 2 , at 37°C for 48 hours. Where indicated, erythrocytes were exposed for 48 hours to exemestane (Selleckchem, Munich, Germany). In order to estimate the impact of Ca 2+ entry on exemestane induced eryptosis, erythrocytes were exposed to exemestane in the presence and absence of extracellular Ca
2+
. To test for an involvement of kinases, erythrocytes were exposed for 48 hours to a combination of exemestane and p38 kinase inhibitor SB203580 (Tocris bioscience, Bristol, UK) or casein kinase inhibitor D4476 (Tocris Bioscience, Bristol, UK). The impact of caspases was elucidated utilizing the pancaspase inhibitor zVAD (Enzo Life Sciences, Lörrach, Germany). To test for the involvement of oxidative stress, experiments were performed in the absence and presence of antioxidant N-acetylcysteine (Sigma Aldrich, Hamburg, Germany).
Annexin-V-binding and forward scatter
After incubation under the respective experimental condition, a 150 µl cell suspension was washed in Ringer solution containing 5 mM CaCl 2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 15 min under protection from light. The annexin-Vabundance at the erythrocyte surface was subsequently determined on a FACS Calibur (BD, Heidelberg, Germany). Annexin-V-binding was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. A marker (M1) was placed to set an arbitrary threshold between annexin-V-binding cells and control cells. The same threshold was used for untreated and exemestane treated erythrocytes. A dot plot of forward scatter (FSC) vs. side scatter (SSC) was set to linear scale for both parameters. The threshold of forward scatter was set at the default value of "52". 
Reactive oxidant species (ROS)
Oxidative stress was determined utilizing 2',7'-dichlorodihydrofluorescein (DCF) diacetate. After incubation, a 150 µl suspension of erythrocytes was washed in Ringer solution and stained with DCF diacetate (Sigma, Schnelldorf, Germany) in Ringer solution containing DCF diacetate at a final concentration of 10 µM. Erythrocytes were incubated at 37°C for 30 min in the dark and washed two times in Ringer solution. The DCF-loaded erythrocytes were resuspended in 200 µl Ringer solution and ROS-dependent fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD). Subsequently, the geomean of the DCF dependent fluorescence was determined.
Ceramide abundance
For the determination of ceramide, a monoclonal antibody-based assay was used. To this end, cells were stained for 1 hour at 37°C with 1 µg/ml anti ceramide antibody (clone MID 15B4, Alexis, Grünberg, Germany) in PBS containing 0.1% bovine serum albumin (BSA) at a dilution of 1:10. The samples were washed twice with PBS-BSA. The cells were stained for 30 minutes with polyclonal fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG and IgM specific antibody (Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-BSA. Unbound secondary antibody was removed by repeated washing with PBS-BSA. The samples were analyzed by flow cytometric analysis with an excitation wavelength of 488 nm and an emission wavelength of 530 nm. Finally, the geomean of the ceramide-dependent fluorescence was determined.
Statistics
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA with Tukey's test as post-test and t test as appropriate. n denotes the number of different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, comparisons were only made to erythrocytes from the same batch.
Results
The present study explored, whether exemestane influences eryptosis, the suicidal erythrocyte death. The decisive hallmark of eryptosis is phospholipid scrambling of the cell membrane with phosphatidylserine translocation to the cell surface. Phosphatidylserine exposing erythrocytes were identified utilizing annexin-V-binding to phosphatidylserine, as determined by flow cytometry. Annexin-V-binding was analysed following an incubation of the erythrocytes for 48 hours in Ringer solution without or with exemestane (10 -40 µg/ ml). As illustrated in Fig. 1 , a 48 hours exposure to exemestane significantly increased the percentage of phosphatidylserine exposing erythrocytes at all exemestane concentrations tested.
A second hallmark of eryptosis is erythrocyte shrinkage. As a measure of erythrocyte volume forward scatter was determined utilizing flow cytometry. The measurements were performed after incubation for 48 hours in Ringer solution without or with exemestane (10 -40 µg/ml). As a result, the erythrocyte forward scatter was similar following exposure in the absence of exemestane (496 ± 5 a.u., n = 24) and in the presence of 10 µg/ml exemestane (476 ± 8 a.u., n = 24), 20 µg/ml exemestane (475± 9 a.u., n = 24) and 40 µg/ml exemestane (468 ± 8 a.u., n = 24). Exemestane did thus not significantly modify erythrocyte volume. ] i . The erythrocytes were analyzed after 48 hours incubation in Ringer solution without or with exemestane (10 -40 µg/ml). As illustrated in Fig. 2 , 48 hours exposure to exemestane increased the Fluo3 fluorescence, an effect reaching statistical significance at 10 and 20 µg/ml, but not at 40 µg/ml exemestane.
In order to test whether exemestane-induced translocation of phosphatidylserine required entry of extracellular Ca . Additional experiments explored whether the stimulation of cell membrane scrambling by exemestane was influenced by increase of extracellular Ca
2+
. As a result, exemestane (40 µg/ml) increased the percentage of phosphatidylserine exposing erythrocytes to similar values following 48 hr incubation at 1 mM extracellular Ca 2+ (from 2.0 ± 0.2 to 9.6 ± 1.6%, n = 37) and at 2 mM extracellular Ca 2+ (from 2.4 ± 0.3 to 10.4 ± 2.3%, n = 12).
Eryptosis is further stimulated by oxidative stress. Reactive oxygen species (ROS) was thus quantified utilizing 2′,7′-dichlorodihydrofluorescein (DCF) diacetate. As illustrated in Fig. 4 , 48 hours exposure to exemestane (40 µg/ml) increased the DCF fluorescence of erythrocytes. Apparently exemestane did induce oxidative stress. The upregulation of DCF fluorescence by exemestane was significantly blunted in the presence of antioxidant N-acetyl-cysteine (Fig. 5A) . In order to test whether extracellular Ca 2+ activity influences oxidative stress, DCF fluorescence was determined in the absence or presence of 40 µg/ . As illustrated in Fig. 5B , removal of extracellular Ca 2+ significantly increased the effect of exemestane on DCF fluorescence. Further experiments addressed whether the effect of exemestane on cell membrane scrambling is sensitive to oxidative stress. To this end, exemestane was applied in the absence and presence of the antioxidant N-acetylcysteine (1 mM). As illustrated in Fig. 5C , N-acetylcysteine significantly blunted the effect of exemestane (40 µg/ml) on the percentage of annexin-V-binding erythrocytes.
A further stimulator of eryptosis is ceramide. Ceramide abundance at the erythrocyte surface was quantified utilizing specific antibodies. As illustrated in Fig. 6 , 48 hours exposure to exemestane (40 µg/ml) increased the ceramide abundance at the erythrocyte surface. In order to test whether ceramide formation is sensitive to extracellular Ca 2+ and/or oxidative stress additional experiments were performed in the presence and nominal absence of extracellular Ca 2+ as well as in the absence and presence of the antioxidant N-acetylcysteine (1 mM). As a result, exemestane (40 µg/ml) increased the ceramide abundance in erythrocytes to similar values following 48 hr incubation at 1 mM extracellular Ca 2+ (from 13.7 ± 1.2 to 19.1 ± 2.4%, n = 10) and at 0 mM extracellular Ca 2+ (from 18.8 ± 2.4 to 21.6 ± 2.3%, n = 10). Moreover, exemestane (40 µg/ml) increased the ceramide abundance in erythrocytes to similar values following 48 hr incubation in the absence (from 15.6 ± 1.2 to 20.2 ± 1.6%, n = 15) and presence (from 17.9 ± 1.5 to 21.4 ± 2.3%, n = 15) of N-acetylcysteine (1 mM). To explore, whether the effects of exemestane involved kinase activity, the exemestaneinduced annexin-V-binding was tested in absence and presence of p38 kinase inhibitor SB203580 and casein kinase inhibitor D4476. As a result, exemestane (40 µg/ml) increased the percentage of phosphatidylserine exposing erythrocytes to similar values following 48 hr incubation in the absence (from 1.5 ± 0.1 to 9.1 ± 1.4%, n = 13) and in the presence (from 1.4 ± 0.1 to 8.5 ± 1.3%, n = 13) of SB203580 (2 µM). Exemestane (40 µg/ml) further increased the percentage of phosphatidylserine exposing erythrocytes to similar values following 48 hr incubation in the absence (from 1.1 ± 0.1 to 7.4 ± 1.1%, n = 5) and in the presence (from 1.0 ± 0.1 to 10.5 ± 1.3%, n = 5) of D4476 (10 µM).
To test whether the effects of exemestane involved caspases, the influence of exemestane on annexin-V-binding was tested in the absence and presence of pancaspase inhibitor zVAD. As a result, exemestane (40 µg/ml) increased the percentage of phosphatidylserine exposing erythrocytes to similar values following 48 hr incubation in the absence (from 1.8 ± 0.1 to 7.6 ± 1.3%, n = 5) and in the presence (from 2.6 ± 0.3 to 13.5 ± 3.9%, n = 5) of zVAD (10 µM). 
Discussion
The present observations uncover a novel effect of exemestane, i.e. the stimulation of cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Breakdown of phospholipid asymmetry of the cell membrane is a hallmark of both, apoptosis and eryptosis. The exemestane concentrations required for the stimulation of cell membrane scrambling are well in the range of concentrations (up to 50 µg/ml) encountered in the plasma of patients [108] . The stimulation of eryptosis may thus well explain the anemia following exemestane treatment [39] .
The effect of exemestane on cell membrane scrambling was paralleled by a slight, but at 10 and 20 µg/ml statistically significant increase of cytosolic Ca 2+ activity ([Ca   2+ ] i ). However, neither removal of extracellular Ca 2+ nor increase of extracellular Ca 2+ to 2 mM did significantly modify exemestane induced cell membrane scrambling. Thus, it appears that exemestane induced erythrocyte cell membrane scrambling was not dependent on entry of extracellular Ca 2+ . In any case, the exemestane induced cell membrane scrambling must involve cellular mechanisms other than increase of [Ca 2+ ] i . A well known additional stimulator of eryptosis is oxidative stress [40] . Exemestane indeed significantly enhanced the abundance of reactive oxygen species. Moreover, the effect of exemestane on cell membrane scrambling was significantly blunted by the antioxidant N-acetylcysteine. Exemestane-induced cell membrane scrambling could thus in part be explained by induction of oxidative stress. Erythrocytes cell membrane scrambling could further be triggered by ceramide [40] . Exemestane treatment indeed increased the ceramide abundance at the erythrocyte surface and the substance may indeed be partially effective by influencing ceramide abundance at the erythrocyte surface. The failure of SB203580, of D4476 and of zVAD to significantly modify exemestane-induced cell membrane sccrambling indicates that the effect of exemestane on cell membrane scrambling does not require activation of p38 kinase, casein kinase or caspases.
In contrast to its effect on cell membrane scrambling exemestane did not appreciably influence erythrocyte forward scatter and thus did apparently not influence erythrocyte volume. Erythrocytes are expected to shrink following increase of [Ca 2+ ] i which is known to stimulate Ca 2+ sensitive K + channels with subsequent K + exit, cell membrane hyperpolarization, Cl -exit and thus cellular loss of KCl with water [40] . Mechanisms accounting for the failure of exemestane to trigger cell shrinkage despite increase of [Ca 2+ ] i remained elusive. Possibly, exemestane leads to cellular energy depletion with subsequent impairment of Na + /K + ATPase activity leading to decrease of cellular K + concentration and thus failure to hyperpolarize following activation of K + channels. Phosphatidylserine exposing erythrocytes are rapidly cleared from circulation blood [40] . The physiological function of eryptosis is the clearance of defective erythrocytes from circulating blood prior to hemolysis [40] . Hemoglobin released following hemolysis may otherwise pass the renal glomerular filter, precipitate in the acidic lumen of renal tubules, occlude nephrons and thus lead to renal failure [109] . The clearance of phosphatidylserine exposing erythrocytes results in anemia if the loss of erythrocytes is not outweighed by matching stimulation of erythropoiesis [40] . Phosphatidylserine exposing erythrocytes may further interfere with microcirculation due to adherence to the vascular wall, stimulation of blood clotting and triggering of thrombosis [40] .
In conclusion, exemestane triggers erythrocyte cell membrane scrambling, an effect paralleled by increase of cytosolic Ca 2+ concentration, oxidative stress and enhancement of ceramide abundance at the erythrocyte surface. The observations provide an explanation for the exemestane-induced anemia.
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